Oppenheimer Issues Pessimistic Forecast for Chemed (NYSE:CHE) Stock Price

Chemed (NYSE:CHE) had its price objective cut by Oppenheimer from $580.00 to $500.00 in a report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target indicates a potential upside of 23.45% from the company’s previous close.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, January 21st. Jefferies Financial Group downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research note on Thursday, January 22nd. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 30th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $422.00 price objective on shares of Chemed in a report on Friday. Two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $498.00.

Chemed Trading Up 2.1%

Shares of NYSE:CHE traded up $8.41 during trading on Friday, reaching $405.04. 25,795 shares of the stock were exchanged, compared to its average volume of 178,630. Chemed has a 12 month low of $385.00 and a 12 month high of $623.60. The firm has a market cap of $5.74 billion, a PE ratio of 21.99, a PEG ratio of 2.27 and a beta of 0.44. The stock has a 50-day moving average price of $446.56 and a 200-day moving average price of $444.05.

Chemed (NYSE:CHE) last announced its earnings results on Wednesday, February 25th. The company reported $6.42 earnings per share for the quarter, missing analysts’ consensus estimates of $7.02 by ($0.60). The firm had revenue of $639.34 million for the quarter, compared to the consensus estimate of $659.09 million. Chemed had a return on equity of 24.70% and a net margin of 10.48%.Chemed’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter last year, the business posted $6.83 EPS. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. On average, sell-side analysts expect that Chemed will post 21.43 earnings per share for the current fiscal year.

Institutional Trading of Chemed

Large investors have recently made changes to their positions in the company. Monetary Solutions Ltd acquired a new position in Chemed during the fourth quarter valued at approximately $25,000. Los Angeles Capital Management LLC bought a new position in shares of Chemed in the 4th quarter valued at $26,000. Smartleaf Asset Management LLC raised its holdings in shares of Chemed by 71.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 60 shares of the company’s stock worth $27,000 after buying an additional 25 shares in the last quarter. BOK Financial Private Wealth Inc. bought a new stake in shares of Chemed during the 4th quarter worth $27,000. Finally, Creekmur Asset Management LLC bought a new stake in shares of Chemed during the 2nd quarter worth $28,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed News Roundup

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: RBC Capital reaffirmed a “sector perform” rating and set a $422 price target (about a mid-single-digit upside vs. recent levels), which may cushion downside and attract value-oriented buyers. Finviz
• Neutral Sentiment: Chemed issued FY‑2026 EPS guidance of $23.25–$24.25 (roughly in line with consensus), and flagged that ~55% of 2026 earnings are expected to be back‑half weighted while forecasting 5.5%–6.5% VITAS revenue growth — guidance reduces surprise risk but signals continued near‑term transition noise. Chemed Reports Fourth-Quarter 2025 Results
• Neutral Sentiment: Company earnings call and multiple transcripts are available for investors to parse management’s details on VITAS recovery plans, Roto‑Rooter performance and cash‑flow dynamics (useful for assessing the credibility of the guidance and timing of any operational turn). Chemed Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed estimates: revenue slightly down year‑over‑year and EPS below consensus; Quiver/press reports highlight declines in gross and operating profit, lower net income and a sharp drop in operating cash flow — the core reason for the immediate stock selloff. Q4 2025 Earnings: Revenue Slightly Down, EPS Miss and Operating Cash Decline
• Negative Sentiment: BofA cut the stock to neutral after the Q4 miss, increasing near‑term analyst pressure and reducing bullish conviction from that shop. Chemed cut to neutral at BofA after Q4 miss
• Negative Sentiment: Johnson Fistel announced an investigation into potential investor claims related to Chemed’s executives, which can increase legal risk and investor uncertainty until resolved. Johnson Fistel Investigation Notice

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.